Epitan files patent, Norwood Abbey granted patent
24 October, 2005 by Ruth BeranMelbourne-based Epitan (ASX:APT, ADR:EPTNY, XETRA:UR9) has filed for a full international patent to protect the commercial use of the topical formulation of its melanin producing drug EPT1647 (formerly Melanotan).
In brief: Regenera, Compumedics, SciGen
21 October, 2005 by Ruth BeranRegenera (ASX:RGA) has appointed Hon Dr Michael Woodridge as non-executive chairman effective immediately, subject to shareholder approval.
Agenix raises AUD$10.3m
21 October, 2005 by Ruth BeranBrisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has raised a total of AUD$10.3 million through a non-renounceable 1:4 entitlements offer.
LCT files for pre-IND meeting with FDA
20 October, 2005 by Helen SchullerLiving Cell Technologies (ASX:LCT) has filed a request for a pre-IND meeting with the US FDA to seek guidance and feedback on the development program for its NeurotrophinCell (NtCell) product for the treatment of Huntington's disease.
In brief: MediVac, C3, Premier Bionics
20 October, 2005 by Ruth BeranBob Atwill will join MediVac (ASX:MDV) as a consultant to assist in the commercialisation of the company's MetaMizer series II. Atwill was formerly sales and marketing director of London Stock Exchange listed orthopaedic company Corin Group.
Resolution in sight for Ventracor and HeartWare legal dispute
19 October, 2005 by Helen SchullerVentracor (ASX:VCR) and HeartWare (ASX:HTW) have commenced negotiations to settle an on-going patent dispute between the two artificial heart firms.
Premier Bionics plans AIM listing
19 October, 2005 by Ruth BeranPremier Bionics (ASX:PBI) is seeking to list on London's Alternative Investment Market (AIM).
Epitan raises AUD$6.9 m, plans AIM listing
19 October, 2005 by Ruth BeranMelbourne-based Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has raised AUD$6.9 million before costs via a private placement to institutional and private investors and will once again seek to list on London's AIM stock market.
Acrux's US partner completes enrolment for phase III trial
18 October, 2005 by Ruth BeranMelbourne-based Acrux's (ASX:ACR) US partner Vivus (NASDAQ:VVUS) has completed enrolment for its phase III clinical study of Acrux's estradiol transdermal spray product Evamist for the treatment of menopausal symptoms.
Phylogica signs licensing deal, collaborates with UWA
18 October, 2005 by Ruth BeranPhylogica (ASX:PYC) has signed a licensing deal with Massachusetts General Hospital and Johns Hopkins University to give the Perth-based company access to a new genetic screening technology.
Positive FDA meeting speeds Mesoblast trials
17 October, 2005 by Helen SchullerMelbourne-based Mesoblast (ASX:MSB) has accelerated its clinical program for obtaining regulatory approvals for its adult stem cell platform technology following a successful pre-investigational new drug (IND) meeting with the US FDA.
Queensland Biobus stops at Gympie
17 October, 2005 by Helen SchullerThe Queensland BioBus is stopping in Gympie this week to encourage more young people to take up a career in science.
Chinese companies invest in Melbourne
14 October, 2005 by Ruth BeranMelbourne biotech is benefiting from a recent business mission to China led by the city's Lord Mayor John So.
In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems
14 October, 2005 by Staff WritersLiving Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies.
Resonance Health patent granted
13 October, 2005 by Ruth BeranPerth based Resonance Health (ASX:RHT) has been granted its first European patent.
